From the Vascular Medicine and Atherosclerosis Unit of the Cardiovascular
Division, Brigham and Women's Hospital (S.B.W., F.K.T., H.H.T., M.-A.
R., M.A.C.) and the Endocrine Division of the Brigham and Women's
Hospital and the Joslin Diabetes Center (A.B.G., D.C.S.), Harvard Medical
School, Boston, Mass.
Correspondence to Mark A. Creager, MD, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115. E-mail macreager{at}bics.bwh.harvard.edu
Methods and ResultsEndothelium-dependent
vasodilation was assessed through brachial artery infusion of
methacholine chloride both before and during 6 hours of local
hyperglycemia (300 mg/dL) achieved by intra-arterial
infusion of 50% dextrose. Forearm blood flow was determined by
plethysmography. In a group of 10 subjects, there was a trend toward
attenuated methacholine-mediated vasodilation during hyperglycemia
compared with euglycemia (P=.07 by ANOVA; maximal
response, 13.3±2.8 versus 14.7±1.5 mL ·
min-1 · 100 mL-1, respectively). In
these subjects, the systemic serum insulin levels increased
significantly during the dextrose infusion (P<.001). To
eliminate the confounding vasoactive effects of insulin, the protocol
was repeated during systemic infusion of octreotide (30 ng ·
kg-1 · min-1) to inhibit pancreatic
secretion of insulin. In these subjects (n=10), hyperglycemia
significantly attenuated the forearm blood flow response to
methacholine (P<.01 by ANOVA; maximal response,
16.9±2.5 before versus 12.7±1.8 mL · min-1
· 100 mL-1 during hyperglycemia). Methacholine-mediated
vasodilation was not attenuated by an equimolar infusion of mannitol
(P>.40), nor did hyperglycemia reduce
endothelium-independent vasodilation to
verapamil (P>.50).
ConclusionsAcute hyperglycemia impairs
endothelium-dependent vasodilation in healthy humans in
vivo. This finding suggests that elevated glucose may contribute to the
endothelial dysfunction observed in patients with
diabetes mellitus.
There is substantial evidence that vasodilation mediated by
endothelium-derived nitric oxide is impaired in animal
models of diabetes4 5 6 7 8 and in patients both with
insulin-dependent9 10 11 and
noninsulin-dependent12 13 14 diabetes mellitus.
Nitric oxide possesses a variety of antiatherogenic properties,
including inhibition of leukocyte adhesion,15
platelet aggregation,16 and vascular smooth
muscle proliferation.17 Thus, the pathogenesis of
diabetic vascular disease may involve an abnormality in the
bioavailability of endothelium-derived nitric oxide,
contributing to the development and pathological consequences of
atherosclerosis through loss of these protective
properties.
The factors that contribute to endothelial dysfunction
in diabetes are currently unknown. Hyperglycemia is the hallmark of
diabetes mellitus, and recent large-scale clinical trials have
correlated poor glycemic control with an increased incidence of both
microvascular18 and
macrovascular19 20 disease. Furthermore, acute
hyperglycemia attenuates endothelium-dependent
vasodilation in normal rabbit aortas in vitro21
and in normal rat arterioles in vivo,22
suggesting high glucose levels may mediate the abnormality.
Accordingly, the objective of this study was to test the hypothesis
that acute hyperglycemia impairs endothelium-dependent
vasodilation in nondiabetic humans in vivo.
Protocol
The effect of acute hyperglycemia on
endothelium-dependent vasodilation was examined in 10
healthy, nondiabetic subjects. First, during fasting euglycemia,
methacholine chloride was administered through the brachial artery in
increasing concentrations (0.3, 1.0, 3.0, and 10.0 µg/min) to assess
vasodilation to endothelium-derived nitric oxide. Basal
conditions were reestablished after waiting
Effect of Hyperglycemia on the Response to Methacholine During
Concomitant Infusion of Octreotide
Effect of Hyperglycemia on the Response to Verapamil
Effect of Hyperosmolality on the Response to Methacholine
Techniques
Biochemical Analyses
Hemodynamic Measurements
Statistical Analyses
Effect of Hyperglycemia on the Response to Methacholine
(Without Octreotide)
Intra-arterial infusion of methacholine chloride increased
forearm blood flow during both euglycemia and hyperglycemia (Figure 1
However, systemic insulin levels were found to increase significantly
during the forearm glucose infusion (Table 2
There were no systemic effects of the methacholine infusion either
before or during forearm hyperglycemia as measured by contralateral
forearm blood flow, change in mean arterial pressure, or
heart rate during drug administration.
Effect of Hyperglycemia on the Response to Methacholine (With
Octreotide)
The vasodilative response to methacholine was attenuated significantly
during hyperglycemia compared with euglycemia (Figure 2
Effect of Hyperglycemia on the Response to Verapamil
Effect of Hyperosmolality on the Response to Methacholine
Evidence of Endothelial Dysfunction in
Diabetes Mellitus
The mechanism(s) of endothelial dysfunction in diabetes
are unknown. Although the deficit may be secondary to comorbid
conditions, including hypertension and dyslipidemia, many
clinical studies demonstrating endothelial dysfunction
in diabetes were control-matched for these parameters.
Recent clinical trials have demonstrated that glycemic control predicts
the incidence of not only microvascular
complications18 but also coronary artery
disease19 and peripheral
arterial disease.20 The effect of
acute hyperglycemia on endothelial function has been
examined in animals in vitro and in vivo. Tesfamariam et
al21 reported that rings of rabbit aorta
incubated in 44 mmol/L (790 mg/dL) glucose showed significantly
decreased endothelium-dependent relaxation to
acetylcholine compared with rings incubated in glucose solutions of
5.5 mmol/L (99 mg/dL) and 11 mmol/L (198 mg/dL). Furthermore,
relaxation in response to the endothelium-independent
agent sodium nitroprusside was not different between rings exposed to
control and elevated glucose, indicating that the
hyperglycemia-mediated deficit is limited to the
endothelium. Similarly, Bohlen and
Lash22 demonstrated in vivo that glucose
concentrations of 300 mg/dL (16.7 mmol/L) and 500 mg/dL (27.8
mmol/L) significantly suppressed the vasodilatory response to
acetylcholine but not nitroprusside. Our study is the first to
demonstrate defective nitric oxidemediated vasodilation during acute
hyperglycemia in humans in vivo. Of relevant interest is the recent
report by Giugliano et al,29 who found that the
hemodynamic and rheological disturbances
induced by systemic hyperglycemia were replicated by the nitric oxide
synthase antagonist L-NMMA and reversed by
L-arginine, implicating reduced availability of nitric
oxide during hyperglycemia. These data, however, contrast with those of
Houben et al,30 who failed to demonstrate
impaired nitric oxidemediated vasodilation in the human forearm
during acute hyperglycemia. Several possibilities exist for the
discrepant results. Houben and colleagues30 did
not clamp insulin, and elevated insulin levels observed during
hyperglycemia could have resulted in insulin-mediated vasodilation;
furthermore, the subject's vasodilatory response was compared on
separate days with potential error resulting from inherent
physiological variability as manifest by the large
confidence intervals.
Mechanisms of Hyperglycemia-Mediated Endothelial
Dysfunction
Hyperglycemia-mediated activation of protein kinase C has also been
postulated to contribute to the vascular dysfunction in diabetes
mellitus.46 Cultured vascular cells exposed to
elevated glucose concentrations in vitro exhibit increased synthesis of
diacylglycerol which results in activation of protein kinase
C.47 Protein kinase C activators
reproduce the abnormalities in vascular function observed during
hyperglycemia,38 47 48 and protein kinase C
inhibitors restore vascular function in both acute
hyperglycemia48 and diabetic animal
models.47 49 Several mechanisms have been
proposed to account for the effect of activated protein kinase
C on endothelium-dependent vasodilation, including
increased generation of vasoconstrictor
prostanoids46 and phosphorylation
of endothelial cell muscarinic
receptors.50 However, activation of protein
kinase C has also been linked to nitric oxide synthesis and
activity.51 52 Inhibition of protein kinase C
results in upregulation of endothelial nitric oxide
synthase,52 and the brain isoform of nitric oxide
synthase has regulatory sites for protein kinase C, which, when
phosphorylated, effect significantly decreased nitric
oxide activity.51 Furthermore, protein kinase C
has been shown to contribute to the formation of oxygen-derived free
radicals53 54 with possible resultant
inactivation of nitric oxide.
Advanced glycosylation end products, which form during
hyperglycemia via nonenzymatic protein glycosylation and cross-linking
reactions, also could contribute to the endothelial
dysfunction observed in diabetes. Advanced glycosylation end
products inactivate nitric oxide in vitro and inhibit
nitric oxidemediated vasodilation.8
Furthermore, incubation of rat aortic rings with glycosylated human
hemoglobin inhibits endothelium-dependent relaxation in
vitro.55 Although our data do not exclude this
theory as a contributing factor to the endothelial
dysfunction in clinical diabetes, the deficit demonstrated in this
study in nondiabetic patients occurs after a time interval of
hyperglycemia too brief for significant formation of advanced
glycosylation end products.
Study Limitations
Baseline forearm blood flow of the healthy nondiabetic study subjects
increased significantly during acute local hyperglycemia.
Insulin-mediated vasodilation could not account for this increase in
flow because it could be reproduced during insulin suppression with
octreotide. Furthermore, studies that demonstrate insulin-mediated
vasodilation require insulin levels in the range of 50 to 70 µU/mL
and do not occur at levels of <10 µU/mL.23 24
(Despite this fact, insulin has been shown to potentiate the
vasodilator response to methacholine,25 rendering
suppression of pancreatic insulin secretion with octreotide requisite
to eliminate confounding.) The augmented baseline forearm blood flow
during hyperglycemia may be secondary to the hyperosmolality associated
with hyperglycemia rather than to a biochemical effect of elevated
glucose per se, as demonstrated by the increase in baseline blood flow
observed in the mannitol control studies. However, because
endothelium-dependent vasodilation remained intact
during mannitol infusion despite a similar increase in baseline blood
flow, the acute hyperperfusion during hyperglycemia/hyperosmolality
could not account for the endothelial dysfunction
observed during hyperglycemia.
Conclusions
Received October 18, 1997;
revision received December 29, 1997;
accepted January 1, 1998.
2.
Ruderman NB, Haudenschild C. Diabetes as an
atherogenic factor. Prog Cardiovasc Dis. 1984;26:373412.[Medline]
[Order article via Infotrieve]
3.
Merimee TJ. Diabetic retinopathy: a
synthesis of perspectives. N Engl J Med. 1990;322:978983.[Medline]
[Order article via Infotrieve]
4.
Oyama Y, Kawasaki H, Hattori Y, Kanno M. Attenuation
of endothelium-dependent relaxation in aorta from
diabetic rats. Eur J Pharmacol. 1986;132:7578.[Medline]
[Order article via Infotrieve]
5.
Meraji S, Jayakody L, Senaratne MP, Thomson AB,
Kappagoda T. Endothelium-dependent relaxation in aorta
of BB rat. Diabetes. 1987;36:978981.[Abstract]
6.
Mayhan WG. Impairment of
endothelium-dependent dilatation of cerebral arterioles
during diabetes mellitus. Am J Physiol. 1989;256:H621H625.
7.
Tesfamariam B, Jakubowski JA, Cohen RA. Contraction of
diabetic rabbit aorta caused by endothelium-derived
PGH2-TxA2. Am J
Physiol. 1989;257:H1327H1333.
8.
Bucala R, Tracey KJ, Cerami A. Advanced glycosylation
products quench nitric oxide and mediate defective
endothelium-dependent vasodilatation in experimental
diabetes. J Clin Invest. 1991;87:432438.
9.
Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK,
Creager MA. Impaired endothelium-dependent vasodilation
in patients with insulin-dependent diabetes mellitus.
Circulation. 1993;88:25102516.
10.
Calver A, Collier J, Vallance P. Inhibition and
stimulation of nitric oxide synthesis in the human forearm
arterial bed of patients with insulin-dependent diabetes.
J Clin Invest. 1992;90:25482554.
11.
Elliott TG, Cockcroft JR, Groop PH, Viberti GC, Ritter
JM. Inhibition of nitric oxide synthesis in forearm vasculature of
insulin-dependent diabetic patients: blunted vasoconstriction in
patients with microalbumineria. Clin Sci. 1993;85:687693.[Medline]
[Order article via Infotrieve]
12.
Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager
MA. Impaired nitric oxide-mediated vasodilation in patients with
non-insulin-dependent diabetes mellitus. J Am Coll
Cardiol. 1996;27:567574.[Abstract]
13.
Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P,
Creager MA. Vitamin C improves endothelium-dependent
vasodilation in patients with non-insulin-dependent diabetes mellitus.
J Clin Invest. 1996;97:2228.[Medline]
[Order article via Infotrieve]
14.
McVeigh GE, Brennan GM, Johnston GD, McDermott BJ,
McGrath LT, Henry WR, Andrews J, Hayes JR. Impaired
endothelium-dependent and independent vasodilation in
type 2 (non-insulin-dependent) diabetes mellitus.
Diabetologia. 1992;35:771776.[Medline]
[Order article via Infotrieve]
15.
Kubes P, Suzuki M, Granger DN. Nitric oxide: an
endogenous modulator of leukocyte adhesion. Proc Natl
Acad Sci U S A. 1991;88:46514655.
16.
Radomski MW, Palmer RM, Moncada S. An
L-arginine/nitric oxide pathway present in human
platelets regulates aggregation. Proc Natl Acad Sci
U S A. 1990;87:51935197.
17.
Garg UC, Hassid A. Nitric oxide-generating vasodilators
and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and
proliferation of cultured rat vascular smooth muscle cells.
J Clin Invest. 1989;83:17741777.
18.
The Diabetes Control, and Complications Trial Research
Group. The effect of intensive treatment of diabetes on the development
and progression of long-term complications in insulin-dependent
diabetes mellitus. N Engl J Med. 1993;329:977986.
19.
Kuusisto J, Mykkanen L, Pyorala K, Laakso M. NIDDM and
its metabolic control predict coronary heart
disease in elderly subjects. Diabetes. 1994;43:960967.[Abstract]
20.
Beks PJ, Mackaay AJ, de Neeling JN, de Vries H, Bouter
LM, Heine RJ. Peripheral arterial disease in
relation to glycaemic level in an elderly Caucasian population: the
Hoorn study. Diabetologia. 1995;38:8696.[Medline]
[Order article via Infotrieve]
21.
Tesfamariam B, Brown ML, Deykin D, Cohen RA. Elevated
glucose promotes generation of endothelium-derived
vasoconstrictor prostanoids in rabbit aorta. J Clin
Invest. 1990;85:929932.
22.
Bohlen HG, Lash JM. Topical hyperglycemia rapidly
suppresses EDRF-mediated vasodilation of normal rat arterioles.
Am J Physiol. 1993;265:H219H225.
23.
Creager MA, Liang CS, Coffman JD. Beta
adrenergic-mediated vasodilator response to insulin in the human
forearm. J Pharmacol Exp Ther. 1985;235:709714.
24.
Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL.
Hyperinsulinemia produces both sympathetic neural
activation and vasodilation in normal individuals. J Clin
Invest. 1991;87:22462252.
25.
Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron
AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide
dependent: a novel action of insulin to increase nitric oxide release.
J Clin Invest. 1994;94:11721179.
26.
Scherrer U, Randin D, Vollenweider P, Vollenweider L,
Nicod P. Nitric oxide release accounts for insulin's vascular effects
in humans. J Clin Invest. 1994;94:25112515.
27.
Moller N, Bagger JP, Schmitz O, Jorgensen JO, Ovesen P,
Moller J, Alberti KG, Orskov H. Somatostatin enhances
insulin-stimulated glucose uptake in the perfused human forearm.
J Clin Endocrinol Metab. 1995;80:17891793.[Abstract]
28.
Soeldner JS, Slone D. Critical variables in the
radio-immunoassay of serum insulin using the double antibody technique.
Diabetes. 1965;14:771779.[Medline]
[Order article via Infotrieve]
29.
Guigliano D, Marfella R, Coppola L, Verrazzo G,
Acampora R, Giunta R, Nappo F, Lucarelli C, D'Onofrio F. Vascular
effects of acute hyperglycemia in humans are reversed by
L-arginine. Circulation. 1997;95:17831790.
30.
Houben AJ, Schaper NC, de Haan CH, Huvers FC, Slaaf DW,
de Leeuw PW, Kruseman AC. Local 24-h hyperglycemia does not affect
endothelium-dependent or -independent vasoreactivity in
humans. Am J Physiol. 1996;270:H2014H2020.
31.
Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion
is involved in the breakdown of endothelium-derived
vascular relaxing factor. Nature. 1986;320:454456.[Medline]
[Order article via Infotrieve]
32.
Mugge A, Elwell JH, Peterson TE, Harrison DG. Release
of intact endothelium-derived relaxing factor depends
on endothelial superoxide dismutase activity.
Am J Physiol. 1991;260:C219C225.
33.
Rubanyi GM, Vanhoutte PM. Oxygen-derived free radicals,
endothelium, and responsiveness of vascular smooth
muscle. Am J Physiol. 1986;250:H815H821.
34.
Kontos HA, Wei EP, Ellis EF, Jenkins LW, Povlishock JT,
Rowe GT, Hess ML. Appearance of superoxide anion radical in cerebral
extracellular space during increased prostaglandin
synthesis in cats. Circ Res. 1985;57:142151.
35.
Kukreja RC, Kontos HA, Hess ML, Ellis EF. PGH synthase
and lipoxygenase generate superoxide in the presence of
NADH and NADPH. Circ Res. 1986;59:612619.
36.
Kontos HA. Oxygen radicals from
arachidonate metabolism in abnormal vascular
responses. Am Rev Respir Dis. 1987;136:474477.[Medline]
[Order article via Infotrieve]
37.
Brown ML, Jakubowski JA, Leventis LL, Deykin D.
Elevated glucose alters eicosanoid release from porcine aortic
endothelial cells. J Clin Invest. 1988;82:21362141.
38.
Wolf BA, Williamson JR, Easom RA, Chang K, Sherman WR,
Turk J. Diacylglycerol accumulation and microvascular abnormalities
induced by elevated glucose levels. J Clin Invest. 1991;87:3138.
39.
Wolff SP, Dean RT. Glucose autoxidation and protein
modification: the potential role of `autoxidative glycosylation' in
diabetes. Biochem J. 1987;245:243250.[Medline]
[Order article via Infotrieve]
40.
Hunt JV, Smith CC, Wolff SP. Autoxidative glycosylation
and possible involvement of peroxides and free radicals in LDL
modification by glucose. Diabetes. 1990;39:14201424.[Abstract]
41.
Tesfamariam B, Cohen RA. Free radicals mediate
endothelial cell dysfunction caused by elevated
glucose. Am J Physiol. 1992;263:H321H326.
42.
Hattori Y, Kawasaki H, Abe K, Kanno M. Superoxide
dismutase recovers altered endothelium-dependent
relaxation in diabetic rat aorta. Am J Physiol. 1991;261:H1086H1094.
43.
Langenstroer P, Pieper GM. Regulation of spontaneous
EDRF release in diabetic rat aorta by oxygen free radicals.
Am J Physiol. 1992;263:H257H265.
44.
Pieper GM, Mei DA, Langenstroer P, O'Rourke ST.
Bioassay of endothelium-derived relaxing factor in
diabetic rat aorta. Am J Physiol. 1992;263:H676H680.
45.
Timimi FK, Ting HH, Boles KS, Roddy MA. Acute vitamin C
administration improves endothelium-dependent
vasodilation in insulin-dependent diabetic patients. J Am
Coll Cardiol. 1996;27:177A. Abstract.
46.
Tesfamariam B. Free radicals in diabetic
endothelial cell dysfunction. Free Radic Biol
Med. 1994;16:383391.[Medline]
[Order article via Infotrieve]
47.
Shiba T, Inoguchi T, Sportsman JR, Heath WF, Bursell S,
King GL. Correlation of diacylglycerol level and protein kinase C
activity in rat retina to retinal circulation. Am J
Physiol. 1993;265:E783E793.
48.
Tesfamariam B, Brown ML, Cohen RA. Elevated glucose
impairs endothelium-dependent relaxation by activating
protein kinase C. J Clin Invest. 1991;87:16431648.
49.
Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont
A, Bursell SE, Kern TS, Ballas LM, Heath WF, Stramm LE, Feener EP, King
GL. Amelioration of vascular dysfunctions in diabetic rats by an oral
PKC beta inhibitor. Science. 1996;272:728731.[Abstract]
50.
Richardson RM, Ptasienski J, Hosey MM. Functional
effects of protein kinase C-mediated phosphorylation of
chicken heart muscarinic cholinergic receptors. J Biol
Chem. 1992;267:1012710132.
51.
Bredt DS, Ferris CG, Snyder SH. Nitric oxide synthase
regulatory sites: phosphorylation by cyclic
AMP-dependent protein kinase, protein kinase C, and
calcium/calmodulin protein kinase; identification of flavin
and calmodulin binding sites. J Biol Chem. 1992;267:1097610981.
52.
Ohara Y, Sayegh HS, Yamin JJ, Harrison DG. Regulation
of endothelial constitutive nitric oxide synthase by
protein kinase C. Hypertension. 1995;25:415420.
53.
Matsubara T, Ziff M. Increased superoxide anion release
from human endothelial cells in response to
cytokines. J Immunol. 1986;137:32953298.[Abstract]
54.
Ohara Y, Peterson TE, Zheng B, Kuo JF, Harrison DG.
Lysophosphatidylcholine increases vascular superoxide anion
production via protein kinase C activation. Arterioscler
Thromb. 1994;14:10071013.
55.
Rodriguez-Manas L, Arribas S, Giron C, Villamor J,
Sanchez-Ferrer CF, Marin J. Interference of glycosylated human
hemoglobin with endothelium-dependent responses.
Circulation. 1993;88:21112116.
© 1998 American Heart Association, Inc.
Clinical Investigation and Reports
Acute Hyperglycemia Attenuates Endothelium-Dependent Vasodilation in Humans In Vivo
![]()
Abstract
Top
Abstract
Introduction
Methods
Results
Discussion
References
BackgroundEndothelial
function is impaired in patients with diabetes mellitus. However, the
factors contributing to this defect are currently unknown.
Hyperglycemia attenuates endothelium-dependent
relaxation in normal rabbit arteries in vitro and rat arterioles in
vivo. Accordingly, this study examined the effect of acute
hyperglycemia on endothelium-dependent vasodilation in
nondiabetic humans in vivo.
Key Words: diabetes mellitus endothelium-derived factors vasodilation glucose nitric oxide
![]()
Introduction
Top
Abstract
Introduction
Methods
Results
Discussion
References
Diabetes mellitus is
associated with accelerated atherosclerosis and
increased prevalence of cardiovascular
disease.1 Both macrovascular disease (resulting
in myocardial infarction, stroke, and claudication) and microvascular
disease (resulting in diabetic nephropathy and
retinopathy) are more prevalent in diabetic than in
nondiabetic populations and contribute importantly to the morbidity
associated with this disease.1 2 3
![]()
Methods
Top
Abstract
Introduction
Methods
Results
Discussion
References
Subjects
Protocols were approved by Brigham and Women's Hospital Human
Research Committee, and written informed consent was obtained from
healthy volunteers recruited from the Boston area through newspaper
advertisements. All subjects underwent screening medical history,
physical examination, and laboratory analyses, which included
complete blood count, serum electrolytes, blood urea nitrogen,
creatinine, fasting glucose, and transaminases. Exclusion
criteria included tobacco use; hypertension; elevated LDL
cholesterol (
75th percentile for age and sex); cardiac or
pulmonary disease; or use of any antihypertensive, cardiac, or
vasoactive medication.
Subjects were studied in the morning in the postabsorptive
state. Cyclooxygenase inhibitors were
prohibited for 72 hours and alcohol and caffeine for 12 hours before
the study. Under local anesthesia and sterile conditions, a
20-gauge Teflon catheter was inserted into the brachial artery for
determination of blood pressure and infusion of drugs.
Arterial blood samples were obtained at baseline for serum
insulin, glucose, and glycosylated hemoglobin. Venous catheters were
inserted into the antecubital fossa of both the study arm and the
contralateral control arm for measurement of local and systemic glucose
and insulin concentrations. The vascular research laboratory was quiet,
the lights were dimmed, and the room temperature was 23°C. Subjects
rested for 30 minutes after catheter placement to establish a stable
baseline before data acquisition.
30 minutes. Then, the
forearm glucose concentration was raised and clamped at 300 mg/dL
(16.7 mmol/L) through intra-arterial infusion of 50%
dextrose at a rate determined by a glucose mass balance (described
below). Venous glucose samples in the infused study arm were monitored
to document that the desired level of hyperglycemia was achieved and
maintained. Systemic glucose and insulin samples were obtained via the
contralateral venous cannula. After 6 hours of local hyperglycemia
(based on the in vitro investigations by Tesfamariam and
colleagues21 ), the methacholine dose-response was
reevaluated. The dextrose infusion rate was proportionally increased at
each dose of methacholine to continue to maintain the forearm glucose
at 300 mg/dL (16.7 mmol/L) despite methacholine-mediated increases
in forearm blood flow. The methacholine dose-response curves obtained
before and during hyperglycemia were compared to determine the effect
of acute hyperglycemia on endothelium-dependent
vasodilation.
Although the primary objective was to increase forearm glucose
concentration, systemic insulin levels increased significantly during
the dextrose infusion in the initial protocol (see "Results").
Insulin is a known vasodilator,23 24 and several
lines of evidence suggest that insulin-mediated vasodilation is
achieved via endothelial release of nitric oxide;
insulin-mediated vasodilation is inhibited by the nitric oxide synthase
antagonist,
WG-monomethyl-L-arginine
(L-NMMA),25 26 and concomitant insulin infusion
augments local vasodilation to methacholine.25 To
eliminate potential confounding vasoactive effects of insulin, a
similar protocol was performed in 10 additional healthy subjects during
concomitant inhibition of pancreatic insulin secretion with octreotide.
The octreotide infusion (30 ng ·
kg-1 · min-1) was
begun 30 minutes before the baseline methacholine dose-response
measurement and was continued at a constant rate through the duration
of the protocol to ensure identical systemic concentrations of
octreotide during both euglycemia and hyperglycemia. This design
eliminates possible confounding from vasoactive effects of octreotide.
Importantly, however, no vasoactive effects of octreotide were
identified in recent studies using identical doses of the
drug.27 The methacholine dose-response curves
obtained during euglycemia and hyperglycemia were compared to determine
the effect of acute hyperglycemia on
endothelium-dependent vasodilation.
To examine the possibility that the attenuated vasodilation
during acute hyperglycemia is not confined to the
endothelium, a subset of 7 of the 10 subjects was
reevaluated on a separate day with the calcium channel blocker
verapamil administered at doses of 10, 30, 100, and 300
µg/min before and after 6 hours of hyperglycemia as described, along
with octreotide. The verapamil dose-response curves
obtained during euglycemia and hyperglycemia were compared to determine
the effect of acute hyperglycemia on
endothelium-independent vasodilation.
As a time and osmolality control, the octreotide protocol was
again repeated in a subset of 7 of the 10 participants by replacing the
dextrose infusion with an equimolar infusion of 25% mannitol. Venous
samples from the infused study arm were obtained throughout the
protocol to document the achieved level of hyperosmolality. The
methacholine dose-response curves obtained before and during the
intra-arterial mannitol infusion were compared to determine
the effect of acute hyperosmolality on
endothelium-dependent vasodilation.
Forearm Hyperglycemic Clamp Method
A forearm hyperglycemic clamp was used to raise and maintain the
forearm glucose concentration at 300 mg/dL (16.7 mmol/L). The
dextrose infusion rate was calculated from a mass balance equation by
multiplying the measured forearm blood flow by the difference of the
desired (300 mg/dL) and systemic glucose concentration measured in the
contralateral arm. The infusion rate determined by this method proved
slightly lower than required because of variable uptake and
utilization of glucose by forearm tissues. Therefore, the calculated
infusion rate was used as the starting infusion rate, and the forearm
glucose concentration was monitored and infusion rate was adjusted
empirically every 10 to 30 minutes until steady state was achieved.
Whole-blood glucose concentration was measured at the bedside by
the glucose oxidase method with a glucose reflectometer; however, the
reported values represent analyses performed on plasma
with a Glucose Analyzer II (Beckman Instruments Inc) at the
conclusion of each study. Insulin was measured by a radioimmunoassay
technique.28 Osmolality was determined by
measurement of freezing point depression. All samples for glucose,
insulin, and osmolality were performed in duplicate.
Bilateral forearm blood flow was determined by venous occlusion
mercury-in-Silastic strain-gauge plethysmography by the methods
described previously.12 Arterial
blood pressure was measured via the arterial cannula, which
was attached to a pressure transducer aligned to an amplifier on a
physiological recorder. Forearm vascular
resistance was calculated as the ratio of mean blood pressure to
forearm blood flow and is expressed in arbitrary units (AU). The heart
rate was determined from a simultaneously obtained ECG and
was calculated from the RR interval.
Data are presented as mean±SE. Comparisons of baseline
forearm blood flow, osmolality, and glucose and insulin concentrations
before and during hyperglycemia were made by use of paired two-tailed
t tests. Statistical analyses on the dose-response
curves for each drug (methacholine chloride or verapamil)
were conducted on the absolute increase and the percentage increase in
forearm blood flow from baseline. Two-way repeated-measures ANOVA was
performed to compare the dose-response curves obtained before and
during the hyperglycemic clamp. Statistical significance was accepted
at the 95% confidence level (P
.05).
![]()
Results
Top
Abstract
Introduction
Methods
Results
Discussion
References
Baseline Values of the Study Populations
Baseline characteristics of the healthy, nondiabetic study
subjects are summarized in Table 1
. The
two methacholine chloride protocols, without and with octreotide,
represent distinct populations. The 7 study subjects in the
verapamil and mannitol protocols represent a random
subset of the 10 volunteers from the octreotide protocol. Serum
insulin, glucose, glycohemoglobin, mean arterial pressure,
and lipid profiles of all subjects were within normal limits.
View this table:
[in a new window]
Table 1. Characteristics of the Study Populations
The initial protocol was designed to evaluate the independent
effect of acute, isolated forearm hyperglycemia on
endothelium-dependent vasodilation. In fact, the
forearm hyperglycemic clamp increased and maintained the glucose
concentration in the study arm as desired, and the corresponding
osmolality increased proportionally (Table 2
). The baseline forearm blood flow in
the study arm increased significantly during hyperglycemia (Table 2
);
similarly, the baseline forearm vascular resistance fell from 47±5 AU
during euglycemia to 32±4 AU during hyperglycemia (P<.05).
The heart rate, mean arterial pressure, and contralateral
forearm blood flow were all unaffected by the
intra-arterial dextrose infusion.
View this table:
[in a new window]
Table 2. Baseline Parameters Before and During
Hyperglycemic Clamping
). There was a trend toward attenuated
methacholine-induced vasodilation during hyperglycemia compared with
euglycemia. At the highest dose of methacholine (10 µg/min), forearm
blood flow increased by only 13.3±2.8 mL ·
min-1 · 100 mL-1
during hyperglycemia compared with 14.7±1.5 mL ·
min-1 · 100 mL-1
during euglycemia (P=.07, ANOVA). When analyzed as
percent change from baseline to control for the augmented baseline
blood flow observed during the dextrose infusion, a significant
attenuation of methacholine-mediated vasodilation was demonstrated
during hyperglycemia (575±80% during hyperglycemia versus 901±180%
during euglycemia; P<.05, ANOVA).

View larger version (16K):
[in a new window]
Figure 1. Absolute increase in forearm blood flow from
baseline during graded intra-arterial infusion of
methacholine chloride both before and during hyperglycemic clamping
(without octreotide). There was a trend toward attenuated vasodilation
during hyperglycemia compared with euglycemia as analyzed by
repeated-measures ANOVA (P=.07).
) (P<.001,
paired t test). Furthermore, the increase in systemic
insulin levels correlated inversely with the severity of attenuated
endothelium-dependent vasodilation (P<.01)
and therefore suggested possible confounding by insulin-mediated
vasodilation.
In the series of experiments including the octreotide infusion,
the forearm glucose concentration achieved by the hyperglycemic
clamping method again was close to the target of 300 mg/dL (16.7
mmol/L), whereas the systemic insulin concentration remained unchanged
(Table 2
). Baseline forearm blood flow again increased significantly
during hyperglycemia (Table 2
), and baseline forearm vascular
resistance fell proportionally (47±4 before versus 30±4 AU during
hyperglycemia, P<.001).
). At the highest dose of methacholine,
the forearm blood flow increased by 16.9±2.5 mL ·
min-1 · 100 mL-1
during euglycemia but only by 12.7±1.8 mL ·
min-1 · 100 mL-1
during hyperglycemia (P<.01, ANOVA). Similarly, the
methacholine-mediated percent increase in forearm blood flow was
attenuated during hyperglycemia (911±150% versus 456±70%,
respectively; P<.001, ANOVA).

View larger version (16K):
[in a new window]
Figure 2. Absolute increase in forearm blood flow from
baseline during graded intra-arterial infusion of
methacholine chloride and concomitant pancreatic inhibition with
octreotide both before and during hyperglycemic clamping. The response
to methacholine chloride was significantly attenuated during
hyperglycemia compared with euglycemia as analyzed by
repeated-measures ANOVA (P<.01).
The effects of hyperglycemia on the baseline forearm blood flow,
osmolality, and systemic insulin concentration in the 7 subjects
participating in the verapamil protocol (Table 2
) were
similar to those observed during the methacholine series. The
verapamil infusion increased forearm blood flow both before
and during hyperglycemia (Figure 3
).
However, in contrast to the findings with methacholine, neither the
vasodilator response (14.2±1.9 mL ·
min-1 · 100 mL-1
euglycemia versus 16.1±2.3 mL ·
min-1 · 100 mL-1
hyperglycemia; P>.50, ANOVA) nor the percent increase in
forearm blood flow (776±100% versus 712±100%, respectively;
P>.30, ANOVA) to verapamil was attenuated
during hyperglycemia. There was no change in forearm blood flow in the
contralateral arm, nor was there a change in blood pressure or heart
rate during verapamil either before or during
hyperglycemia.

View larger version (15K):
[in a new window]
Figure 3. Absolute increase in forearm blood flow from
baseline during graded intra-arterial infusion of
verapamil both before and during hyperglycemic clamping. No
significant difference in the response to verapamil was
seen between euglycemic and hyperglycemic states as
analyzed by repeated-measures ANOVA
(P>.50).
As a time and osmolality control, the octreotide protocol was
repeated in a subset of 7 of the 10 subjects by replacing the dextrose
infusion with an equimolar mannitol infusion. The increase in
osmolality with mannitol was comparable to that observed overall in the
hyperglycemia protocols (Table 2
) and in the subset of 7 patients who
received both dextrose and mannitol (280±3 to 303±5 mosm/kg and
282±1 to 301±3 mosm/kg, respectively; P>.60, ANOVA).
Neither the serum glucose nor insulin concentrations were significantly
affected by the mannitol infusion (Table 2
). Baseline forearm blood
flow increased significantly during the infusion of mannitol (Table 2
),
and the corresponding baseline forearm vascular resistance decreased
from 48±5 to 27±3 AU during hyperosmolality (P<.001).
Forearm blood flow increased significantly in response to methacholine
chloride before and during the mannitol infusion (Figure 4
). However, in contrast to
hyperglycemia, there was a trend toward augmented (rather than
attenuated) methacholine-mediated vasodilation during hyperosmolality.
At the maximal dose of methacholine, forearm blood flow increased by
13.5±2.1 mL · min-1 · 100
mL-1 before mannitol and by 18.6±3.6 mL
· min-1 · 100
mL-1 during the mannitol infusion
(P>.40, ANOVA), and the percent increase in blood flow to
methacholine was unchanged during hyperosmolality (702±90% versus
611±90%, P>.20).

View larger version (17K):
[in a new window]
Figure 4. Absolute increase in forearm blood flow from
baseline during graded intra-arterial infusion of
methacholine chloride both before and during hyperosmolar clamping.
There was no significant effect of osmolality on the response to
methacholine chloride as analyzed by repeated-measures ANOVA
(P>.40).
![]()
Discussion
Top
Abstract
Introduction
Methods
Results
Discussion
References
These experiments demonstrate that
endothelium-dependent vasodilation is attenuated by
acute hyperglycemia in healthy, nondiabetic humans in vivo. The
attenuated response to methacholine chloride but not to the calcium
channel blocker verapamil indicates that the deficit
involves endothelium-derived nitric oxide. Control
studies with equimolar infusions of mannitol indicate that the
attenuated response observed during hyperglycemia cannot be attributed
either to hyperosmolality or to protocol duration.
Extensive evidence exists for endothelial
dysfunction in diabetes mellitus. Multiple investigators have
demonstrated nitric oxidemediated vasomotor dysfunction in animal
models of diabetes4 5 6 7 8 and in humans in vivo. We
and others have demonstrated that nitric oxidemediated vasodilation
is blunted in patients both with
noninsulin-dependent12 13 14 and
insulin-dependent diabetes mellitus.9 10 11
Investigations in animal models are beginning to elucidate the
biochemical mechanism(s) by which hyperglycemia induces
endothelial dysfunction. Potential mechanisms include
hyperglycemia-mediated formation of oxygen-derived free radicals,
activation of protein kinase C, and formation of advanced glycosylation
end products. Free radicals inactivate
endothelium-derived nitric
oxide,31 32 interfere with
endothelium-dependent
vasodilation,33 and are produced during
prostaglandin formation.34 35 36
Increased prostaglandin synthesis has been demonstrated in
models of both acute21 37 and
chronic7 38 hyperglycemia. Moreover, nitric
oxidemediated vasodilation is restored by blockade of
prostaglandin synthesis,6 7 21 22
consistent with prostanoid-mediated free radical formation.
Alternatively, hyperglycemia may lead directly to formation of free
radicals by glucose auto-oxidation.39 40 Studies
with antioxidants support hyperglycemia-induced free radical formation.
Endothelial dysfunction resulting from both acute
hyperglycemia22 41 and chronic states of
hyperglycemia in experimental diabetes42 43 44 can
be reversed by pretreatment with free radical scavengers. Furthermore,
we have previously demonstrated that
endothelium-dependent vasodilation is restored both in
patients with noninsulin-dependent diabetes13
and insulin-dependent diabetes45 by the
short-term administration of the antioxidant vitamin C.
Octreotide has well-documented systemic effects (including
suppression of multiple pancreatic, adrenocortical, and pituitary
hormones) and therefore had the potential to confound our
analysis of the independent effect of hyperglycemia on
endothelial function. However, the fact that
methacholine-induced vasodilation was blunted during hyperglycemia with
or without octreotide, combined with the fact that methacholine-induced
vasodilation was attenuated during octreotide/glucose but not
octreotide/mannitol infusions, makes it unlikely that the results of
this study were attributable either directly or indirectly to the
octreotide. Furthermore, the octreotide protocols were designed so that
the systemic octreotide levels were identical during both euglycemia
and hyperglycemia.
These studies demonstrate that acute hyperglycemia impairs
endothelium-dependent vasodilation in nondiabetic
humans in vivo, implicating elevated glucose as a cause of the
endothelial dysfunction in patients with diabetes. Our
data may provide insight into the vasculoprotective effects of strict
glycemic control that have been observed in clinical trials. However,
blood glucose concentrations in diabetic patients cannot be completely
normalized even under optimal conditions, and most patients eventually
develop vascular complications. Understanding the mechanism(s) by which
acute hyperglycemia impairs endothelial function in
diabetes mellitus may lead to secondary preventive strategies to reduce
cardiovascular morbidity and mortality in this highly
prevalent disease.
![]()
Acknowledgments
This research was supported by a National Institutes of Health
Program Project Grant in Vascular Biology and Medicine (HL-48743)
and by a National Institutes of Health grant provided to the Brigham
and Women's Hospital General Clinical Research Center (NCRR GCRC
M01-RR-02635). Dr Creager is a recipient of a National Heart, Lung, and
Blood Institute Academic Award in Systemic and Pulmonary
Vascular Medicine (HL-02663).
![]()
References
Top
Abstract
Introduction
Methods
Results
Discussion
References
1.
National Diabetes Data Group. Diabetes in
America: Diabetes Data Compiled 1984. Bethesda, Md.: National
Institutes of Health; 1985. NIH publication 851468.
This article has been cited by other articles:
![]() |
C. G. Parkin, D. Hinnen, R. K. Campbell, P. Geil, D. L. Tetrick, and W. H. Polonsky Effective Use of Paired Testing in Type 2 Diabetes: Practical Applications in Clinical Practice The Diabetes Educator, November 1, 2009; 35(6): 915 - 927. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Davidson and C. G. Parkin Is Hyperglycemia a Causal Factor in Cardiovascular Disease?: Does proving this relationship really matter? Yes Diabetes Care, November 1, 2009; 32(suppl_2): S331 - S333. [Full Text] [PDF] |
||||
![]() |
M. Hanefeld, S. R. Bornstein, and F. Pistrosch Shifting the Disease Management Paradigm From Glucose: What are the cons? Diabetes Care, November 1, 2009; 32(suppl_2): S353 - S356. [Full Text] [PDF] |
||||
![]() |
J. Xu and M.-H. Zou Molecular Insights and Therapeutic Targets for Diabetic Endothelial Dysfunction Circulation, September 29, 2009; 120(13): 1266 - 1286. [Full Text] [PDF] |
||||
![]() |
A. Soylu, K. Ozdemir, M. A. Duzenli, M. Yazici, and M. Tokac Impact on Diabetes Mellitus on the Epicardial Coronary Flow Velocity Assessed by the Thrombolysis in Myocardial Infarction Frame Count Angiology, August 1, 2009; 60(4): 431 - 440. [Abstract] [PDF] |
||||
![]() |
D. Aguilar, B. Bozkurt, K. Ramasubbu, and A. Deswal Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes. J. Am. Coll. Cardiol., July 28, 2009; 54(5): 422 - 428. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Lavi, A. Karasik, N. Koren-Morag, H. Kanety, M. S. Feinberg, and M. Shechter The acute effect of various glycemic index dietary carbohydrates on endothelial function in nondiabetic overweight and obese subjects. J. Am. Coll. Cardiol., June 16, 2009; 53(24): 2283 - 2287. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Crandall, H. Shamoon, H. W. Cohen, M. Reid, S. Gajavelli, G. Trandafirescu, V. Tabatabaie, and N. Barzilai Post-Challenge Hyperglycemia in Older Adults Is Associated with Increased Cardiovascular Risk Profile J. Clin. Endocrinol. Metab., May 1, 2009; 94(5): 1595 - 1601. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Bjarnegard, H. J Arnqvist, T.;r. Lindstro;m, L. Jonasson, and T. Lanne Long-term hyperglycaemia impairs vascular smooth muscle cell function in women with type 1 diabetes mellitus Diabetes and Vascular Disease Research, January 1, 2009; 6(1): 25 - 31. [Abstract] [PDF] |
||||
![]() |
C. Jarnert, L. Landstedt-Hallin, K. Malmberg, A. Melcher, J. Ohrvik, H. Persson, and L. Ryden A randomized trial of the impact of strict glycaemic control on myocardial diastolic function and perfusion reserve: a report from the DADD (Diabetes mellitus And Diastolic Dysfunction) study Eur J Heart Fail, January 1, 2009; 11(1): 39 - 47. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Cosentino, L. Rydén, P. Francia, and L. G. Mellbin CHAPTER 14 Diabetes Mellitus and Metabolic Syndrome ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. G. Camici, F. Cosentino, F. C. Tanner, and T. F. Luscher The role of p66Shc deletion in age-associated arterial dysfunction and disease states J Appl Physiol, November 1, 2008; 105(5): 1628 - 1631. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Matsumoto, E. Noguchi, K. Ishida, T. Kobayashi, N. Yamada, and K. Kamata Metformin normalizes endothelial function by suppressing vasoconstrictor prostanoids in mesenteric arteries from OLETF rats, a model of type 2 diabetes Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1165 - H1176. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. B. Dokken The Pathophysiology of Cardiovascular Disease and Diabetes: Beyond Blood Pressure and Lipids Diabetes Spectr, July 1, 2008; 21(3): 160 - 165. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Balzer, T. Rassaf, C. Heiss, P. Kleinbongard, T. Lauer, M. Merx, N. Heussen, H. B. Gross, C. L. Keen, H. Schroeter, et al. Sustained benefits in vascular function through flavanol-containing cocoa in medicated diabetic patients a double-masked, randomized, controlled trial. J. Am. Coll. Cardiol., June 3, 2008; 51(22): 2141 - 2149. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Esposito, M. Ciotola, D. Carleo, B. Schisano, L. Sardelli, D. Di Tommaso, L. Misso, F. Saccomanno, A. Ceriello, and D. Giugliano Post-Meal Glucose Peaks at Home Associate with Carotid Intima-Media Thickness in Type 2 Diabetes J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1345 - 1350. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Cosentino, P. Francia, G. G. Camici, P. G. Pelicci, M. Volpe, and T. F. Luscher Final Common Molecular Pathways of Aging and Cardiovascular Disease: Role of the p66Shc Protein Arterioscler Thromb Vasc Biol, April 1, 2008; 28(4): 622 - 628. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Fernandez, C. Triplitt, E. Wajcberg, A. A. Sriwijilkamol, N. Musi, K. Cusi, R. DeFronzo, and E. Cersosimo Addition of Pioglitazone and Ramipril to Intensive Insulin Therapy in Type 2 Diabetic Patients Improves Vascular Dysfunction by Different Mechanisms Diabetes Care, January 1, 2008; 31(1): 121 - 127. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Wadham, A. Parker, L. Wang, and P. Xia High Glucose Attenuates Protein S-Nitrosylation in Endothelial Cells: Role of Oxidative Stress Diabetes, November 1, 2007; 56(11): 2715 - 2721. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Zheng, M. Patel, R. Cable, L. Young, and S. D. Katz Insulin Sensitivity, Vascular Function, and Iron Stores in Voluntary Blood Donors Diabetes Care, October 1, 2007; 30(10): 2685 - 2689. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Muniyappa, M. Montagnani, K. K. Koh, and M. J. Quon Cardiovascular Actions of Insulin Endocr. Rev., August 1, 2007; 28(5): 463 - 491. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Hovorka, J. Kremen, J. Blaha, M. Matias, K. Anderlova, L. Bosanska, T. Roubicek, M. E. Wilinska, L. J. Chassin, S. Svacina, et al. Blood Glucose Control by a Model Predictive Control Algorithm with Variable Sampling Rate Versus a Routine Glucose Management Protocol in Cardiac Surgery Patients: A Randomized Controlled Trial J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 2960 - 2964. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. H. McNulty, M. A. Tulli, B. J. Robertson, V. Lendel, L. A. Harach, S. Scott, and J. P. Boehmer Effect of simulated postprandial hyperglycemia on coronary blood flow in cardiac transplant recipients Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H103 - H108. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M Hartge, T. Unger, and U. Kintscher The endothelium and vascular inflammation in diabetes Diabetes and Vascular Disease Research, June 1, 2007; 4(2): 84 - 88. [Abstract] [PDF] |
||||
![]() |
Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. V. d. Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur. Heart J. Suppl., June 1, 2007; 9(suppl_C): C3 - C74. [Full Text] [PDF] |
||||
![]() |
M. Ishihara, I. Inoue, T. Kawagoe, Y. Shimatani, S. Kurisu, T. Hata, Y. Nakama, Y. Kijima, and E. Kagawa Is admission hyperglycaemia in non-diabetic patients with acute myocardial infarction a surrogate for previously undiagnosed abnormal glucose tolerance? Eur. Heart J., October 2, 2006; 27(20): 2413 - 2419. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Viswanathan, J.-P. Guichard, A. Gschwendtner, F. Buffon, R. Cumurcuic, C. Boutron, E. Vicaut, M. Holtmannspotter, C. Pachai, M.-G. Bousser, et al. Blood pressure and haemoglobin A1c are associated with microhaemorrhage in CADASIL: a two-centre cohort study Brain, September 1, 2006; 129(9): 2375 - 2383. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Giugliano, A. Ceriello, and K. Esposito The Effects of Diet on Inflammation: Emphasis on the Metabolic Syndrome J. Am. Coll. Cardiol., August 15, 2006; 48(4): 677 - 685. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Barsheshet, M. Garty, E. Grossman, A. Sandach, B. S. Lewis, S. Gottlieb, A. Shotan, S. Behar, A. Caspi, R. Schwartz, et al. Admission Blood Glucose Level and Mortality Among Hospitalized Nondiabetic Patients With Heart Failure. Arch Intern Med, August 14, 2006; 166(15): 1613 - 1619. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. R. Mohler III, G. Lech, G. E. Supple, H. Wang, and B. Chance Impaired Exercise-Induced Blood Volume in Type 2 Diabetes With or Without Peripheral Arterial Disease Measured by Continuous-Wave Near-Infrared Spectroscopy Diabetes Care, August 1, 2006; 29(8): 1856 - 1859. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. Goldfine, J. A. Beckman, R. A. Betensky, H. Devlin, S. Hurley, N. Varo, U. Schonbeck, M. E. Patti, and M. A. Creager Family History of Diabetes Is a Major Determinant of Endothelial Function J. Am. Coll. Cardiol., June 20, 2006; 47(12): 2456 - 2461. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yasuda, S. Miyazaki, M. Kanda, Y. Goto, M. Suzuki, Y. Harano, and H. Nonogi Intensive treatment of risk factors in patients with type-2 diabetes mellitus is associated with improvement of endothelial function coupled with a reduction in the levels of plasma asymmetric dimethylarginine and endogenous inhibitor of nitric oxide synthase Eur. Heart J., May 2, 2006; 27(10): 1159 - 1165. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R. Gosmanov, F. B. Stentz, and A. E. Kitabchi De novo emergence of insulin-stimulated glucose uptake in human aortic endothelial cells incubated with high glucose Am J Physiol Endocrinol Metab, March 1, 2006; 290(3): E516 - E522. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ishii, S. Ichimiya, M. Kanashiro, T. Amano, T. Matsubara, and T. Murohara Effects of Intravenous Nicorandil Before Reperfusion for Acute Myocardial Infarction in Patients With Stress Hyperglycemia Diabetes Care, February 1, 2006; 29(2): 202 - 206. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Nieuwdorp, T. W. van Haeften, M. C.L.G. Gouverneur, H. L. Mooij, M. H.P. van Lieshout, M. Levi, J. C.M. Meijers, F. Holleman, J. B.L. Hoekstra, H. Vink, et al. Loss of Endothelial Glycocalyx During Acute Hyperglycemia Coincides With Endothelial Dysfunction and Coagulation Activation In Vivo Diabetes, February 1, 2006; 55(2): 480 - 486. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Chen, R. J. Karne, G. Hall, U. Campia, J. A. Panza, R. O. Cannon III, Y. Wang, A. Katz, M. Levine, and M. J. Quon High-dose oral vitamin C partially replenishes vitamin C levels in patients with Type 2 diabetes and low vitamin C levels but does not improve endothelial dysfunction or insulin resistance Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H137 - H145. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. K. LeBrasseur and N. B. Ruderman Why Might Thiazolidinediones Increase Exercise Capacity in Patients With Type 2 Diabetes? Diabetes Care, December 1, 2005; 28(12): 2975 - 2977. [Full Text] [PDF] |
||||
![]() |
B. Capaldo, M. Galderisi, A. A. Turco, A. D'Errico, S. Turco, A. A. Rivellese, G. de Simone, O. de Divitiis, and G. Riccardi Acute Hyperglycemia Does Not Affect the Reactivity of Coronary Microcirculation in Humans J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 3871 - 3876. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Libby, D. M. Nathan, K. Abraham, J. D. Brunzell, J. E. Fradkin, S. M. Haffner, W. Hsueh, M. Rewers, B. T. Roberts, P. J. Savage, et al. Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus Circulation, June 28, 2005; 111(25): 3489 - 3493. [Full Text] [PDF] |
||||
![]() |
G. T. McMahon, J. Plutzky, E. Daher, T. Bhattacharyya, G. Grunberger, and M. F. DiCarli Effect of a Peroxisome Proliferator-Activated Receptor-{gamma} Agonist on Myocardial Blood Flow in Type 2 Diabetes Diabetes Care, May 1, 2005; 28(5): 1145 - 1150. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. A. McAlister, S. R. Majumdar, S. Blitz, B. H. Rowe, J. Romney, and T. J. Marrie The Relation Between Hyperglycemia and Outcomes in 2,471 Patients Admitted to the Hospital With Community-Acquired Pneumonia Diabetes Care, April 1, 2005; 28(4): 810 - 815. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Stalker, Y. Gong, and R. Scalia The Calcium-Dependent Protease Calpain Causes Endothelial Dysfunction in Type 2 Diabetes Diabetes, April 1, 2005; 54(4): 1132 - 1140. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Chan, K. Inouye, E. Akirav, E. Park, M. C. Riddell, M. Vranic, and S. G. Matthews Insulin Alone Increases Hypothalamo-Pituitary-Adrenal Activity, and Diabetes Lowers Peak Stress Responses Endocrinology, March 1, 2005; 146(3): 1382 - 1390. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ceriello Acute hyperglycaemia: a 'new' risk factor during myocardial infarction Eur. Heart J., February 2, 2005; 26(4): 328 - 331. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Kaufmann and P. G. Camici Myocardial Blood Flow Measurement by PET: Technical Aspects and Clinical Applications J. Nucl. Med., January 1, 2005; 46(1): 75 - 88. [Full Text] [PDF] |
||||
![]() |
D. L. Katz, M. A. Evans, W. Chan, H. Nawaz, B. P. Comerford, M. L. Hoxley, V. Y. Njike, and P. M. Sarrel Oats, Antioxidants and Endothelial Function in Overweight, Dyslipidemic Adults J. Am. Coll. Nutr., October 1, 2004; 23(5): 397 - 403. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Flibotte, N. Hagan, J. O'Donnell, S. M. Greenberg, and J. Rosand Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage Neurology, September 28, 2004; 63(6): 1059 - 1064. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Aguilar, S. D. Solomon, L. Kober, J.-L. Rouleau, H. Skali, J. J.V. McMurray, G. S. Francis, M. Henis, C. M. O'Connor, R. Diaz, et al. Newly Diagnosed and Previously Known Diabetes Mellitus and 1-Year Outcomes of Acute Myocardial Infarction: The Valsartan in Acute Myocardial Infarction (VALIANT) Trial Circulation, September 21, 2004; 110(12): 1572 - 1578. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. R. Saunders and M. E. Tschakovsky Evidence for a rapid vasodilatory contribution to immediate hyperemia in rest-to-mild and mild-to-moderate forearm exercise transitions in humans J Appl Physiol, September 1, 2004; 97(3): 1143 - 1151. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Chu and H. G. Bohlen High concentration of glucose inhibits glomerular endothelial eNOS through a PKC mechanism Am J Physiol Renal Physiol, September 1, 2004; 287(3): F384 - F392. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. A. Mullan, C. N. Ennis, H. J. P. Fee, I. S. Young, and D. R. McCance Protective effects of ascorbic acid on arterial hemodynamics during acute hyperglycemia Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1262 - H1268. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Weisbrod, P. R. Eastwood, G. O'Driscoll, J. H. Walsh, M. Best, J. R. Halliwill, and D. J. Green Vasomotor Responses to Hypoxia in Type 2 Diabetes Diabetes, August 1, 2004; 53(8): 2073 - 2078. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H. Endemann and E. L. Schiffrin Endothelial Dysfunction J. Am. Soc. Nephrol., August 1, 2004; 15(8): 1983 - 1992. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Jorgensen, T. Jenssen, O. Joakimsen, I. Heuch, O. C. Ingebretsen, and B. K. Jacobsen Glycated Hemoglobin Level Is Strongly Related to the Prevalence of Carotid Artery Plaques With High Echogenicity in Nondiabetic Individuals: The Tromso Study Circulation, July 27, 2004; 110(4): 466 - 470. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. I. Barzilay, R. A. Kronmal, J. S. Gottdiener, N. L. Smith, G. L. Burke, R. Tracy, P. J. Savage, and M. Carlson The association of fasting glucose levels with congestive heart failure in diabetic adults >=65 years: The Cardiovascular Health Study J. Am. Coll. Cardiol., June 16, 2004; 43(12): 2236 - 2241. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Stranders, M. Diamant, R. E. van Gelder, H. J. Spruijt, J. W. R. Twisk, R. J. Heine, and F. C. Visser Admission Blood Glucose Level as Risk Indicator of Death After Myocardial Infarction in Patients With and Without Diabetes Mellitus Arch Intern Med, May 10, 2004; 164(9): 982 - 988. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Koitka, P. Abraham, B. Bouhanick, D. Sigaudo-Roussel, C. Demiot, and J. L. Saumet Impaired Pressure-Induced Vasodilation at the Foot in Young Adults With Type 1 Diabetes Diabetes, March 1, 2004; 53(3): 721 - 725. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Reed, N. Charkoudian, A. Vella, P. Shah, R. A. Rizza, and M. J. Joyner Forearm vascular control during acute hyperglycemia in healthy humans Am J Physiol Endocrinol Metab, March 1, 2004; 286(3): E472 - E480. [Abstract] [Full Text] |
||||
![]() |
V. Fonseca, C. Desouza, S. Asnani, and I. Jialal Nontraditional Risk Factors for Cardiovascular Disease in Diabetes Endocr. Rev., February 1, 2004; 25(1): 153 - 175. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Clement, S. S. Braithwaite, M. F. Magee, A. Ahmann, E. P. Smith, R. G. Schafer, and I. B. Hirsch Management of Diabetes and Hyperglycemia in Hospitals Diabetes Care, February 1, 2004; 27(2): 553 - 591. [Full Text] [PDF] |
||||
![]() |
M. Raitakari, T. Ilvonen, M. Ahotupa, T. Lehtimaki, A. Harmoinen, P. Suominen, J. Elo, J. Hartiala, and O. T. Raitakari Weight Reduction With Very-Low-Caloric Diet and Endothelial Function in Overweight Adults: Role of Plasma Glucose Arterioscler Thromb Vasc Biol, January 1, 2004; 24(1): 124 - 128. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. T. Hurst and R. W. Lee Increased Incidence of Coronary Atherosclerosis in Type 2 Diabetes Mellitus: Mechanisms and Management Ann Intern Med, November 18, 2003; 139(10): 824 - 834. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Ganz and J. A. Vita Testing Endothelial Vasomotor Function: Nitric Oxide, a Multipotent Molecule Circulation, October 28, 2003; 108(17): 2049 - 2053. [Full Text] [PDF] |
||||
![]() |
M. A. Creager, T. F. Luscher, F. Cosentino, and J. A. Beckman Diabetes and Vascular Disease: Pathophysiology, Clinical Consequences, and Medical Therapy: Part I Circulation, September 23, 2003; 108(12): 1527 - 1532. [Full Text] [PDF] |
||||
![]() |
N. Ihlemann, C. Rask-Madsen, A. Perner, H. Dominguez, T. Hermann, L. Kober, and C. Torp-Pedersen Tetrahydrobiopterin restores endothelial dysfunction induced by an oral glucose challenge in healthy subjects Am J Physiol Heart Circ Physiol, July 11, 2003; 285(2): H875 - H882. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Gerich Clinical Significance, Pathogenesis, and Management of Postprandial Hyperglycemia Arch Intern Med, June 9, 2003; 163(11): 1306 - 1316. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-H. Mak and D. P. Faxon Clinical studies on coronary revascularization in patients with type 2 diabetes Eur. Heart J., June 2, 2003; 24(12): 1087 - 1103. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. A. McAlister, J. Man, L. Bistritz, H. Amad, and P. Tandon Diabetes and Coronary Artery Bypass Surgery: An examination of perioperative glycemic control and outcomes Diabetes Care, May 1, 2003; 26(5): 1518 - 1524. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. F. Di Carli, J. Janisse, G. Grunberger, and J. Ager Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes J. Am. Coll. Cardiol., April 16, 2003; 41(8): 1387 - 1393. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Dunder, L. Lind, B. Zethelius, L. Berglund, and H. Lithell Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study BMJ, March 29, 2003; 326(7391): 681 - 681. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. A. Kingwell, M. Formosa, M. Muhlmann, S. J. Bradley, and G. K. McConell Type 2 Diabetic Individuals Have Impaired Leg Blood Flow Responses to Exercise: Role of endothelium-dependent vasodilation Diabetes Care, March 1, 2003; 26(3): 899 - 904. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. P. Singh, H. Groehn, and A. Kazmers Vascular function and carotid intimal-medial thickness in children with insulin-dependent diabetes mellitus J. Am. Coll. Cardiol., February 19, 2003; 41(4): 661 - 665. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. H. Capell, C. A. DeSouza, P. Poirier, M. L. Bell, B. L. Stauffer, K. M. Weil, T. L. Hernandez, and R. H. Eckel Short-Term Triglyceride Lowering With Fenofibrate Improves Vasodilator Function in Subjects With Hypertriglyceridemia Arterioscler Thromb Vasc Biol, February 1, 2003; 23(2): 307 - 313. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Browne, D. Meeking, K. Shaw, and M. Cummings Review: Endothelial dysfunction and pre-symptomatic atherosclerosis in type 1 diabetes -- pathogenesis and identification The British Journal of Diabetes & Vascular Disease, January 1, 2003; 3(1): 27 - 34. [Abstract] [PDF] |
||||
![]() |
A. Kjaer, C. Meyer, F. S. Nielsen, H.-H. Parving, and B. Hesse Dipyridamole, Cold Pressor Test, and Demonstration of Endothelial Dysfunction: A PET Study of Myocardial Perfusion in Diabetes J. Nucl. Med., January 1, 2003; 44(1): 19 - 23. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Ferrara, G. Guardigli, and R. Ferrari Myocardial metabolism: the diabetic heart Eur. Heart J. Suppl., January 1, 2003; 5(suppl_B): B15 - B18. [Abstract] [PDF] |
||||
![]() |
N. N. Wahab, E. A. Cowden, N. J. Pearce, M. J. Gardner, H. Merry, J. L. Cox, and ICONS Investigators Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era? J. Am. Coll. Cardiol., November 20, 2002; 40(10): 1748 - 1754. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Charkoudian, A. Vella, A. S. Reed, C. T. Minson, P. Shah, R. A. Rizza, and M. J. Joyner Cutaneous vascular function during acute hyperglycemia in healthy young adults J Appl Physiol, October 1, 2002; 93(4): 1243 - 1250. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Dickinson, S. Colagiuri, E. Faramus, P. Petocz, and J. C. Brand-Miller Postprandial Hyperglycemia and Insulin Sensitivity Differ among Lean Young Adults of Different Ethnicities J. Nutr., September 1, 2002; 132(9): 2574 - 2579. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. P. Marso Optimizing the diabetic formulary: beyond aspirin and insulin J. Am. Coll. Cardiol., August 21, 2002; 40(4): 652 - 661. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Carson, P. M. Scholz, A. Y. Chen, E. D. Peterson, J. Gold, and S. H. Schneider Diabetes mellitus increases short-term mortality and morbidity in patients undergoing coronary artery bypass graft surgery J. Am. Coll. Cardiol., August 7, 2002; 40(3): 418 - 423. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. G. Modena, L. Bonetti, F. Coppi, F. Bursi, and R. Rossi Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women J. Am. Coll. Cardiol., August 7, 2002; 40(3): 505 - 510. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Desouza, A. Parulkar, D. Lumpkin, D. Akers, and V. A. Fonseca Acute and Prolonged Effects of Sildenafil on Brachial Artery Flow-Mediated Dilatation in Type 2 Diabetes Diabetes Care, August 1, 2002; 25(8): 1336 - 1339. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. S. Hermann and N. Wiernsperger Impaired glucose tolerance and metformin: clinical and mechanistic aspects The British Journal of Diabetes & Vascular Disease, May 1, 2002; 2(3): 177 - 183. [Abstract] [PDF] |
||||
![]() |
R. W. van Etten, E. J.P. de Koning, M. L. Honing, E. S. Stroes, C. A. Gaillard, and T. J. Rabelink Intensive Lipid Lowering by Statin Therapy Does Not Improve Vasoreactivity in Patients With Type 2 Diabetes Arterioscler Thromb Vasc Biol, May 1, 2002; 22(5): 799 - 804. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Paradisi, A. Biaggi, S. Ferrazzani, S. De Carolis, and A. Caruso Abnormal Carbohydrate Metabolism During Pregnancy : Association with endothelial dysfunction Diabetes Care, March 1, 2002; 25(3): 560 - 564. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. B. Wilkinson, I. R. Hall, H. MacCallum, I. S. Mackenzie, C. M. McEniery, B. J. van der Arend, Y.-E. Shu, L. S. MacKay, D. J. Webb, and J. R. Cockcroft Pulse-Wave Analysis: Clinical Evaluation of a Noninvasive, Widely Applicable Method for Assessing Endothelial Function Arterioscler Thromb Vasc Biol, January 1, 2002; 22(1): 147 - 152. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kelm Flow-mediated dilatation in human circulation: diagnostic and therapeutic aspects Am J Physiol Heart Circ Physiol, January 1, 2002; 282(1): H1 - H5. [Full Text] [PDF] |
||||
![]() |
E. Bonora, F. Calcaterra, S. Lombardi, N. Bonfante, G. Formentini, R. C. Bonadonna, and M. Muggeo Plasma Glucose Levels Throughout the Day and HbA1c Interrelationships in Type 2 Diabetes: Implications for treatment and monitoring of metabolic control Diabetes Care, December 1, 2001; 24(12): 2023 - 2029. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. K. Koh, M. H. Kang, D. K. Jin, S.-K. Lee, J. Y. Ahn, H. Y. Hwang, S. H. Yang, D. S. Kim, T. H. Ahn, and E. K. Shin Vascular effects of estrogen in type II diabetic postmenopausal women J. Am. Coll. Cardiol., November 1, 2001; 38(5): 1409 - 1415. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Rask-Madsen, N. Ihlemann, T. Krarup, E. Christiansen, L. Kober, C. Nervil Kistorp, and C. Torp-Pedersen Insulin Therapy Improves Insulin-Stimulated Endothelial Function in Patients With Type 2 Diabetes and Ischemic Heart Disease Diabetes, November 1, 2001; 50(11): 2611 - 2618. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Kersten, W. G. Toller, J. P. Tessmer, P. S. Pagel, and D. C. Warltier Hyperglycemia reduces coronary collateral blood flow through a nitric oxide-mediated mechanism Am J Physiol Heart Circ Physiol, November 1, 2001; 281(5): H2097 - H2104. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Marfella, F. Nappo, M. A. Marfella, and D. Giugliano Acute Hyperglycemia and Autonomic Function Diabetes Care, November 1, 2001; 24(11): 2016 - 2017. [Full Text] [PDF] |
||||
![]() |
M. A van de Ree, M. V Huisman, F. H de Man, J. C van der Vijver, A.E. Meinders, and G. J Blauw Impaired endothelium-dependent vasodilation in type 2 diabetes mellitus and the lack of effect of simvastatin Cardiovasc Res, November 1, 2001; 52(2): 299 - 305. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Duffy, E. S. Biegelsen, M. Holbrook, J. D. Russell, N. Gokce, J. F. Keaney Jr, and J. A. Vita Iron Chelation Improves Endothelial Function in Patients With Coronary Artery Disease Circulation, June 12, 2001; 103(23): 2799 - 2804. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. Goh, A. C. Shore, M. Quinn, and J. E. Tooke Impaired Microvascular Vasodilatory Function in 3-Month-Old Infants of Low Birth Weight Diabetes Care, June 1, 2001; 24(6): 1102 - 1107. [Abstract] [Full Text] |
||||
![]() |
G. Booth, T. J. Stalker, A. M. Lefer, and R. Scalia Elevated ambient glucose induces acute inflammatory events in the microvasculature: effects of insulin Am J Physiol Endocrinol Metab, June 1, 2001; 280(6): E848 - E856. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1998 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |